RxDoctor Payments DataLook up a doctor →

Marlys Bitner, APRN

Acute Care · Fayetteville, ARNPI 1528172095

Payments from drug & device makers

$8,224in general payments, 2019–2025

Across 474 payments — averaging $17.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • AstraZeneca$1K
  • Boehringer Ingelheim$719
  • Abbott$654
  • Pfizer$523
  • Regeneron Healthcare Solutions, Inc.$432
  • plus $3K from 37 others

What the payments were for

  • Food & beverage$8,05398%
  • Education$1702%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,224 in reported general payments places this provider in the 95th percentile of 321 acute care providers in Arkansas.

See all acute care providers in Arkansas

Medicare billing

Part B allowed, 2024
$37,813
Medicare patients
342
Services billed
481

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prolastin CAlpha-1-Proteinase Inhibitor18$166,175
OfevNintedanib Esylate11$143,193
Trelegy ElliptaFluticasone/Umeclidin/Vilanter140$107,802
Breztri AerosphereBudesonide/Glycopyr/Formoterol59$43,504
Breo ElliptaFluticasone/Vilanterol80$38,646
EliquisApixaban56$31,590
EntrestoSacubitril/Valsartan37$23,239
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr38$18,209
Spiriva HandihalerTiotropium Bromide24$18,199
Spiriva RespimatTiotropium Bromide32$17,681
Incruse ElliptaUmeclidinium Bromide44$15,996
Arnuity ElliptaFluticasone Furoate42$10,347
Advair HfaFluticasone Propion/Salmeterol20$8,940
JardianceEmpagliflozin13$7,887
SymbicortBudesonide/Formoterol Fumarate26$6,550

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$1,699$191,000344 claims
Boehringer IngelheimOfev, Spiriva Respimat, Jardiance, Combivent Respimat$719$173,99967 claims
Grifols USA, LLCProlastin C$107$166,17518 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,461$50,05485 claims
PfizerEliquis$523$31,59056 claims
NovartisEntresto$61$23,23937 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 321 acute care providers in Arkansas.

Other acute care in Fayetteville

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →